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In recent years, scientific societies had warmly embraced nanotechnology as an emerging field in cancer 
therapy. Nanotechnology has had a profound influence on almost every aspect of the twenty-first century’s 
diurnal life. During the past years, nanomaterials have been successfully applied in different biomedical 
fields; especially in cancer therapy. While cancer is one of the deadliest disorders worldwide, there is a 
need to develop novel anticancer approaches. In this review, we explained various kinds of nanoparticles 
such as liposome-based and polymeric nanoparticles and dendrimers along with their applications in 
cancer therapy.
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Introduction
With the emergence of more than 10 million 
new cancer cases every year, the worldwide 
incidence of cancer has rapidly increased in 
the past decades. Treatment of cancer is hard 
delivering malignancies as major causes of 
morbidity and mortality in populations (1). 
Although anticancer drugs can be efficient in 
cancer therapy, their activities and effective 
dosages are generally manipulated by various 
factors. Traditional anti-cancer agents such 
as chemotherapeutic drugs nonspecifically 
target both cancerous and normal cells in 
the body. This event limits the dose of drug 
delivered to tumors resulting in suboptimal 
therapeutic efficiency. 
Targeted therapy has been appeared as an 
approach to overcome unspecific targeting of 
cancer cells by traditional chemotherapeutic 
agents (2). After reaching tumor cells, 
drugs should release their active forms in a 
controlled way to selectively target tumor 
cells without influencing normal tissue. This 
phenomenon is critical for improving both 
quality of life and survival of patients by 
increasing the intracellular concentration of 
drugs and limiting dose-related toxicities. As 
efficient drug carrier systems, nanoparticles 
seem to fulfil both specificity and efficiency 
requirements of cancer therapeutics (3). 
During recent years, researchers have tried to 
develop new diagnostic strategies for cancer. 
In this regard, nanotechnology has been 
under focus as one of the most promising 
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fields to diagnosis and treat cancers.
Nanotechnology is the knowledge of 
engineering substances and practices 
at molecular measure. In medicine, 
comprehensive studies on nanomaterials 
have culminated in their application 
as drug- release vehicles. These nano-
carriers are mostly <100 nm in size and 
have the capability to carry and supply the 
therapeutics agents to intended cells (4).
In cancer treatment, the efficiency of 
nanoparticles depends on their penetrability 
and ability to be stored and retained in tumor 
tissues (5). As mentioned, intravenous 
injection of noxious chemotherapeutic 
drugs poses a critical risk to healthy tissues 
limiting their tolerable doses (6). In brief, 
nanoparticles can increase the intracellular 
absorption of drugs by cancer cells and 
prevent toxicity against normal cells by 
recruiting both passive and active targeting 
approaches (7, 8). Moreover, after binding 
to particular receptors, nanoparticles can 
penetrate into cells as endosomes through 
receptor-mediated endocytosis. In this way, 
they can bypass the action of P-glycoprotein 
as one of the major drug resistance 
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mechanisms in cancerous cells (9). In this review, we 
discussed various nanoparticles used in cancer therapy.
Materials and Methods
For this review, we used a variety of sources including 
PubMed, Web of Science, Embase, EBSCO, Google 
Scholar and Scopus. The search was conducted, using 
combinations of the following key words and or their 
equivalents; cancer, nanoparticles, liposomes, dendrimers, 
albumin, endocytosis, photoluminescence, carbon 
nanotubes and nanomedicine.
Liposomes
Liposomes were introduced by Bangham et al in 1965. 
Liposomes are among very first nanoparticle-based 
platforms utilized for therapeutic purposes (10). They 
consist of amphiphilic lipid molecules gathered into bilayer 
spherical vesicles with an aqueous core and a vesicle shell 
(4,6).
Depending on their designs, liposomes vary in diameter 
ranging from tens of nanometers to micrometers. Features 
such as biocompatibility and biodegradability, in addition 
to the unique capability to encapsulate both hydrophilic 
(inside the aqueous core) and hydrophobic (inside the 
lamellae) drugs deliver liposomes as brilliant drug carriers. 
Likewise, to enhance their constancy and half-life in 
circulation, liposomes can also be covered with polymers 
like polyethylene glycol (11). 
Liposomal medicine formulations usually amend the 
pharmacokinetics and biodistribution of a drug. There are 
currently more than 11 liposomal formulations permitted 
for clinical application, and many other formulations 
are in clinical and preclinical phases (4). The liposomal 
formulations currently used in cancer therapy include 
DepoCyt (12, 13), ONCO-TCS (14), Doxil (15,16) 
and DaunoXome (17,18) which are formulations of 
doxorubicin, daunorubicin, cytarabine and vincristine 
respectively (6).
Another liposome-based formulation has been used to 
co-deliver SiRNAs and chemotherapeutics. SiRNAs are 
developing classes of cancer therapeutics interfering with 
gene expression through targeting mRNAs. In 2008, Saad 
et al developed a liposome system to transport SiRNAs 
targeting BCL2 (a protein responsible for resistance of 
cells to apoptosis) and MRP1 (a multifunctional defiance 
-associated protein) in combination with doxorubicin into 
human H69AR lung cancer cells (19). Table 1 provides a 
brief description regarding anti-cancer liposome-based 
combinational treatments.
Polymeric nanoparticles
Biodegradable and biocompatible polymeric nanoparticles 
have been under investigations to transport and target 
drugs (6). Many polymeric nanoparticles have been 
investigated in comprehensive clinical and preclinical 
studies as biocompatible and biodegradable drug carriers 
(26). 
As polymers propose higher synthetic freedom, they 
allow various particles to be tailored for particular 
clinical needs. Due to these unique properties, polymeric 
nanoparticles have attracted enormous interests among 
scientific and industrial societies even though they are still 
in the early phases of investigations (6). The hydrophobic 
core of polymers is able to carry high amount of drugs 
whereas the hydrophilic shell supplies a steric defense 
for the nanoparticle. Polymeric nanoparticles have also 
been able to encapsulate either micro or macromolecules 
(such as nucleic acids and proteins) with hydrophilic or 
hydrophobic properties (27).
In comparison with liposomes, polymeric nanoparticles 
generally have better stability, sharper size distribution, 
more advantageous physicochemical attributes, sustained 
and more manageable drug-release profiles, and better 
loading capacity for water-insoluble drugs (6).
Dendrimers
Dendrimers are a new class of nanoparticles developed 
as drug-delivery vehicles in cancer therapy. They are 
well described branched spherical macromolecules (28). 
Dendrimers are produced in a stepwise and iterative 
method. The structure of dendrimers constitutes from a 
core surrounded by layers of branched repeated units with 
functional groups on the outmost layer (6).
They are commonly derived from either synthetic or 
natural elements like nucleotides, sugars, and amino 
acids. These nanoparticles can be simply conjugated to 
therapeutics. Through holes in their cores, dendrimers 
can be loaded with drugs via hydrophobic interactions, 
Table 1. Liposome-based combinations used as cancer therapeutics
Formulation Indication Reference
CPX-351 Acute myeloid leukemia (20)
Liposome co-encapsulating 6-mercaptopurine and daunorubicin Acute lymphocytic leukemia (21)
Liposome co-encapsulating quercetin and vincristine Breast cancer (22)
CPX-1 Colorectal cancer (23)
Transferrin-conjugated liposome co-encapsulating doxorubicin and verapamil Leukemia (24)
Cationic liposome co-encapsulating SiRNA and doxorubicin Lung cancer (19)
CPX-571 Small-cell lung cancer (25)
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Metal nanoparticles
In recent years, metal oxide nanoparticles have grabbed 
significant attentions in biomedical fields (37), in particular 
developing nanovaccine scaffolds. Due to their tendency 
to penetrate into a wide range of cells, these nanoparticles 
have also been interesting candidates for cancer therapy 
(38,39). 
Metal oxide nanoparticles have unique physical (e.g. 
fluorescent enhancement and plasmonic resonance) and 
chemical (e.g. catalytic activity) properties delivering 
them appropriate agents as drug carriers (40-47). Metal 
nanoparticles have larger surface area, higher surface 
area to volume ratio, and characteristics physicochemical 
properties (such as high toxicity against cancer cells due 
to structural properties and inducing reactive oxygen 
species, as well as photothermal, and hyperthermia 
effects) which make them potential platforms for cancer 
therapy. Regarding their unique properties such as 
photoluminescence and superparamagnetic attributes, 
metal nanoparticles have also been investigated in 
diagnostic and imaging procedures (41-43). Metallic 
nanoshells which usually contain metals such as gold (Au) 
or titanium (Ti) have been employed to control the gradual 
release of chemotherapeutic agents in tumor tissues (45-
47).
Silica nanoparticles
Silica is a critical constituent of human cells. Amorphous 
silica is a nontoxic, biocompatible and biodegradable agent 
that is widely distributed throughout the human body and 
excreted in urine (48).
For the first time, Unger-K et al, conjugated drugs to 
sol-gel derivative of silica (SiO2) in 1983 (49). Since then, 
silica-based substances have been well characterized as 
drugs and molecules carriers (50,53), gene transfection 
elements (51) and cell identifiers (52). 
A challenging problem in cancer treatment is the 
unavailability of efficient biocompatible systems to transfer 
many hydrophobic remedial anticancer drugs (54). 
Amongst various drug-delivery methods, mesoporous 
silica substances (55) have been effective in transferring 
water-insoluble medicines. The large surface area and 
spongy interiors of silica substances potentiate them for 
loading large quantities of hydrophobic therapeutics 
(54). On the other hand, mesoporous silica nanoparticles 
including fluorescein isothiocyanate (a widely used 
fluorescence color) are highly biocompatible promising 
an efficient system to deliver hydrophobic anticancer 
medicines (56).
In this regard, in vitro investigations showed that 
mesoporous silica nanoparticles were effective in 
simultaneous delivering of doxorubicin and SiRNA to 
cancer cells promoting the efficiency of chemotherapy (6).
As a matter of fact, the great capacity of mesoporous 
silica substances to absorb drugs can be enhanced by 
controlling their attributes such as the size and the number 
as well as hydrogen, and chemical bonds. The preclinical 
studies on dendrimers have largely focused on developing 
dendrimer-drug conjugates (4).
Collectively, the unique attributes of dendrimers 
make them suitable platforms for simultaneous delivery 
of water soluble and insoluble agents. For example, 
the hydrophobic core of dendrimers includes a hole 
encapsulating hydrophobic drugs. On the other hand, 
the multivalent outer layers can be conjugated with 
hydrophilic medications (6).
Although several attempts have been made to deliver 
multiple drugs using dendritic platforms (6), dendrimers 
have not attracted as much notice as liposomes and 
polymeric nanoparticles. So far, a dendrimer-based 
compound (i.e. 5 poly-propyleneimine) has been 
utilized to co-encapsulate methotrexate (a hydrophobic 
chemotherapeutic) and all-trans retinoic acid (a 
hydrophilic drug with mild anticancer activity) (29,30).
Nanoparticle albumin-bound (nab) technology
Albumin is a vital plasma protein carrying hydrophobic 
molecules by forming reversible noncovalent bonds. 
Albumin is highly concentrated in tumors, and 
therefore nanoparticle albumin-bound (nab) platforms 
can be promising carriers to deliver hydrophobic 
chemotherapeutics to tumors (31). 
The traditional formulations for constructing 
hydrophobic remedial agents use toxic solvents and 
surfactants such as Cremophor EL and Tween. These 
agents can deter the dispersal and delivery of the active 
drug component by micellar sequestration. On the 
contrary, the “nab” technology allows combination of 
hydrophobic molecules with albumin through noncovalent 
hydrophobic interactions to build 50–150 nm colloidal 
nanoparticles (32). These nab-paclitaxel nanoparticles 
have a narrow size distribution with an average particle 
size of round 130 nm as verified by dynamic laser light 
scattering (32, 33). 
Briefly, the “nab” technology is a nanoparticle-based 
drug delivery platform constructed on the unique 
functional attributes of albumin which permits efficient 
diffusion of drug in tumor tissues and obviates the need 
for using toxic solvents (32).
Recent research based on the maximum-tolerated 
dosage showed that antitumor activity of nab-paclitaxel 
was superior or at least equal to that of polysorbate-based 
docetaxel in prostate, breast, colon, and lung cancer 
xenograft models (34). In preclinical investigations on 
pancreatic cancer models, the combinational therapy with 
nab-paclitaxel and gemcitabine showed strong antitumor 
activity with higher concentration of gemcitabine within 
the tumor which may be attributed to either the capability 
of nab-paclitaxel to disturb tumor stroma (35) or reduce 
the activity of cytidine deaminase, the primary gemcitabine 
metabolizing enzyme (36).
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of surface holes of the particles. Furthermore, the capacity 
of mesoporous silica nanoparticles to absorb drugs can 
also be promoted by optimizing medicine incorporation 
environment (57, 58).
Carbon nanotubes 
In recent years, carbon nanotubes (CNTs) have gained 
increasing interests by many scientists worldwide. The 
drug and gene delivery capacities of CNTs along with their 
surface properties and unique physicochemical attributes 
beacon novel and efficient nanomaterial-based systems for 
cancer treatment (59).
Single-wall carbon nanotubes (SWNTs) present notable 
opportunities to address progressive challenges of drug 
delivery methods (60, 61). Some approaches have been 
introduced to link biological molecules such as proteins, 
DNA, and smaller molecules to SWNTs (62, 63). Based 
on their biocompatibility, excretion properties, and minor 
toxicity, chemically functionalized SWNTs have been 
effective in combinational cancer-targeted therapy in mice 
(64).
Overall, functionalized and solubilized SWNTs can carry 
proteins, peptides, DNA, and genes (65, 66) by penetrating 
through cell membranes with minor cytotoxicity (67, 
68). SWNTs present large surface area per unit of weight 
delivering great drug loading capacity (69). In addition, 
in vivo and in vitro studies on cancer cells viability have 
clarified that oxidized SWNTs bio-conjugated with 
cisplatin and epidermal growth factor (EGF) receptor 
ligand can selectively and effectively target squamous 
carcinoma cells overexpressing EGF receptor (59).
Discussion
Targeted delivery
Numerous novel biotechnological methods have 
been developed in the past decades to treat cancer. 
Nanomedicine represents a filed aiming to develop 
diagnostic and therapeutic instruments and approaches 
based on nanoparticles (70). Because of providing safe 
and effective platforms, nanomedicine is rapidly getting 
recognition especially in anticancer therapy (71).
Although chemotherapeutic agents encapsulated within 
nanoparticles are highly powerful against cancer cells, 
they may inflict collateral harms on adjacent healthy 
tissues as well. Therefore, targeted delivery of these 
compounds toward tumor cells is highly important in 
the development of nanoparticle-based therapeutics. 
Although nanoparticles can passively be accumulated 
at the tumor site because of their high permeability and 
stability, active targeting of these compounds can further 
facilitate the process (6). 
Conclusively, nanoparticles encapsulated drugs (such 
as Genexol- PM 1 and Doxil 1) boost pharmaceutical 
solubility and pharmacokinetic properties of drugs and 
lessen the cytotoxicity of chemotherapeutics in used for 
cancer therapy (71). 
Recent studies have confirmed that liposomes, polymeric 
nanoparticles and dendrimers have surface functional 
groups which can be conjugated with target ligands such 
as antibodies (4, 6,72, 73), peptides (Lyp1 and RGD) (74), 
oligonucleotides (aptamers) (75) and antibody variants 
(single-chain changeable pieces and diabodies) (76) to 
specifically target drugs toward tumors.
Although nanoparticles as drug carriers have many 
benefits, there are still many limitations such as poor oral 
bioavailability, week traceability in circulation, insufficient 
tissue supply, and toxicity which need to be resolved.
Conclusion
As mentioned, the unique attributes of nanoparticle-based 
drug carriers generate suitable agents for therapeutic 
purposes in oncology. While nanomedicine is a 
comparatively novel science, it is rapidly transforming into 
a practical field in medicine. Nanoparticle-encapsulated 
chemotherapeutics are expected to attain widespread 
applications as cancer therapeutics in the future. In spite 
of this, limited number of them have been approved for 
clinical use, and there are still disadvantages needed to be 
resolved before their widespread clinical application. More 
clinical studies are required to completely understand the 
benefits and harms of nanoparticle remedials.
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